Non-Profits

Found 4,832 articles

• The American Diabetes Association Welcomes 2024 Principal Officers and Members to the National Board of Directors

  1/3/2024

  The American Diabetes Association® welcomes the 2024 principal officers and board of directors.

• Molecular Diagnostics Research That Could Transform Healthcare Featured in the January Issue of ADLM's The Journal of Applied Laboratory Medicine

  1/3/2024

  Molecular diagnostics is a powerful branch of laboratory medicine that examines the fundamental genetic and biochemical components of life to provide invaluable insights into health and disease.

• Sail Biomedicines Receives Grants to Fight Malaria by Developing a New Class of RNA Medicines

  1/3/2024

  Sail Biomedicines, Inc. announced that the Company has received two grants from the Bill & Melinda Gates Foundation to advance Sail’s first-in-category Endless RNA™ platform to develop secreted monoclonal antibodies and vaccines for malaria.

• 

  Master AML Trial Gives Patients New Lease on Life

  1/2/2024

  Also called an umbrella or basket trial, the master trial allows for a more targeted approach to cancer treatment, faster patient enrollment and the flexibility to pivot.

• Reactivate, repurpose, and rewire the brain

  12/28/2023

  Developing brains become shaped by the sights, sounds, and experiences of early life. The brain's circuits grow more stable as we age.

• These worms have rhythm

  12/27/2023

  There's a rhythm to developing life. Growing from a tiny cell cluster into an adult organism takes precise timing and control.

• How plants pass down genetic memories

  12/21/2023

  When organisms pass their genes on to future generations, they include more than the code spelled out in DNA. Some also pass along chemical markers that instruct cells how to use that code.

• Harm Reduction Therapeutics Introduces RiVive™, Over-the-Counter Opioid Overdose Reversal Medication

  12/20/2023

  Harm Reduction Therapeutics, an independent, 501 non-profit pharmaceutical company, announced that it has begun shipping RiVive™, an FDA-approved, over-the-counter medication for the emergency treatment of opioid overdose.

• The Scleroderma Research Foundation Announces the Launch of the CONQUEST Trial Platform and IND Clearance

  12/19/2023

  The Scleroderma Research Foundation, the nation's largest non-profit funder of scleroderma research, announced that the FDA has cleared its Investigational New Drug application to launch the CONQUEST clinical trial platform and begin enrolling patients.

• The Foundation for Sarcoidosis Research (FSR) awards $100,000 in support of cardiac sarcoidosis

  12/18/2023

  Foundation for Sarcoidosis Research announces $100,000 in funding for support of research aimed at improving diagnosis, management, and treatment of cardiac sarcoidosis.

• Lung Cancer Research Foundation Announces 2023 Scientific Research Grant Awards

  12/14/2023

  The Lung Cancer Research Foundation® is pleased to announce the awardees of its 2023 Scientific Grant Program.

• New study sheds light on how the brain learns to seek reward

  12/13/2023

  Imagine you're teaching a dog to play fetch. You throw a ball, and your dog sprints after it, picks it up, and runs back. You then reward your panting pup with a treat.

• Scientists unveil first complete cellular map of adult mouse brain

  12/13/2023

  Six years and 32 million cells later, scientists have created the first full cellular map of a mammalian brain.

• Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Young Blood Institute’s AmβARI study on Amyloid Removal

  12/12/2023

  Meilleur Technologies, Inc. announced a research collaboration agreement with the Young Blood Institute on the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography scans to assess the status of amyloid plaque in the brain.

• NEA Awards Grants for Eczema Research Totaling Nearly $1 Million

  12/12/2023

  The National Eczema Association announced the recipients for its 2023 research grants. From both U.S.-based and international applications, the research projects of 18 outstanding investigators were selected, representing grants totaling nearly $1 million.

• NMDP/Be The Match® PTCy Research Levels the Field between Matched and Mismatched Hematopoietic Cell Transplantation

  12/11/2023

  Underscoring its commitment to expanding access to cell and gene therapy, NMDP/Be The Match® presented research at the American Society of Hematology Annual Meeting & Exhibition, which demonstrated that the use of post-transplant cyclophosphamide based graft-versus-host disease prevention significantly reduces the risk of transplant across the human leukocyte antigen barrier and has the potential to level the playing field for patients with mismatched donors.

• Real World Data Shows Impact of Immunotherapy in Populations Underrepresented in Clinical Trials, According to JNCCN Study

  12/11/2023

  New research in the December 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds patients treated with first-line immunotherapy for advanced Non-Small Cell Lung Cancer showed similar results in terms of survival, progression-free survival, and treatment duration, regardless of race or ethnicity, even with differences in income and insurance.

• The Leukemia & Lymphoma Society Honors Five Outstanding Blood Cancer Scientists with 2023 Awards

  12/11/2023

  The Leukemia & Lymphoma Society recognized and celebrated the outstanding contributions of five scientific investigators for their achievements in helping drive forward LLS's work to cure blood cancers and improve the quality of life of patients and their families.

• Lessons Learned From ADLM's COVID Immunity Study Could Improve Research on Future Pandemics

  12/7/2023

  A special report published in the Association for Diagnostics & Laboratory Medicine's The Journal of Applied Laboratory Medicine describes the design, operations, and methodology of the COVID Immunity Study, a large-scale scientific study by ADLM that took place in September 2021.

• Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration

  11/28/2023

  Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.